Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-26 @ 2:12 AM
Study NCT ID:
NCT06926205
Status:
RECRUITING
Last Update Posted:
2025-04-13
First Post:
2025-03-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL
Sponsor:
GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-15
Start Date Type:
ACTUAL
Primary Completion Date:
2028-05-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05-15
Completion Date Type:
ESTIMATED
First Submit Date:
2025-03-17
First Submit QC Date:
None
Study First Post Date:
2025-04-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-07
Last Update Post Date:
2025-04-13
Last Update Post Date Type:
ACTUAL